Prof. dr. Sonja Zweegman bespreekt in dit journaal haar nieuwselectie van EHA 2021 op het gebied van multipel myeloom.
Het nieuws wordt besproken aan de hand van onderstaande EHA-abstracts:
- OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY
- DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE ± DARATUMUMAB AND ASCT: CASSIOPEIA PART 2 RESULTS
- DEPTH OF RESPONSE AND MRD STATUS IN ULTRA HIGH-RISK MYELOMA AND PLASMA CELL LEUKEMIA TREATED WITH DARA-CVRD AND AUGMENTED AUTOLOGOUS TRANSPLANT: RESULTS OF THE RISK-STRATIFIED UK OPTIMUM/MUKNINE TRIAL
- EFFICACY OF CARFILZOMIB-BASED INDUCTION/CONSOLIDATION WITH OR WITHOUT AUTOLOGOUS TRANSPLANT AND LENALIDOMIDE OR CARFILZOMIB-LENALIDOMIDE MAINTENANCE IN HIGH-RISK PATIENTS IN THE FORTE TRIAL
- UPDATED INTERIM ANALYSIS OF THE GMMG-CONCEPT TRIAL INVESTIGATING ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-KRD) IN FRONT-LINE TREATMENT OF HIGH-RISK MULTIPLE MYELOMA
- EFFICACY AND SAFETY OF THE BCMA-DIRECTED CAR-T CELL THERAPY, CILTACABTAGENE AUTOLEUCEL, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1–3 PRIOR LINES OF THERAPY: INITIAL RESULTS FROM CARTITUDE-2
- TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 RESULTS
Bekijk hier het volledige overzicht van onze EHA 2021 coverage.